Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: A randomized phase IV trial

Diabetes, Obesity and Metabolism

Volumn 16, Issue 10, 2014, Pages 963-970

  Tinahones, F J ^a   Gross, J L ^b   Onaca, A ^c   Cleall, S ^d   Rodríguez, Angel ^e  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b Centro de Pesquisas em Diabetes   (Brazil)

^c Department of Psychiatry   (Romania)

^d ELI LILLY AND COMPANY   (United States)

^e Lilly Spain   (Spain)

Author keywords

Insulin glargine; Insulin intensification; Insulin lispro; Insulin lispro mixture; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIET RESTRICTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; MEAL; METABOLISM; MIDDLE AGED;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MEALS; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84912080001     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12303     Document Type: Article

References (21)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
3. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012; 14: 228-233.
4. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327-336.
5. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10: 1178-1185.
6. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab 2011; 13: 1020-1027.
7. Davidson MB, Raskin P, Tanenberg R, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 2011; 17: 395-403.
8. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twicedaily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005; 22: 374-381.
9. Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010; 32: 896-908.
10. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 20-25.
11. Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twicedaily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014; 16: 396-402.
12. Buse JB, Wolffenbuttel BHR, Herman WH et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results. Diabetes Care 2009; 32: 1007-1013.
13. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, AT. LANTUS study group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
14. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. World Health Organization, Department of Noncommunicable Diseases Surveillance, Geneva, Switzerland, 1999. Document WHO/NCD/NCS/99.2.
15. Anderson RT, Skovlund SF, Marrero D et al. Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther 2004; 26: 565-578.
16. Monahan PO, Lane KA, Hayes RP, McHorney CA, Marrero DG. Reliability and validity of an instrument for assessing patients perceptions about medications for diabetes: the PAM-D. Qual Life Res 2009; 18: 941-952.
17. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 2011; 34: 510-517.
18. Edelman SV, Liu R, Johnson J, Glass LC. AUTONOMY: The first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care 2014; 37: 2132-2140.
19. Gumprecht J, Benroubi M, Borzi V et al. IMPROVE study group expert panel. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009; 63: 966-972.
20. Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010; 56: e418-e424.
21. Liebl A, Jones S, Goday A et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther 2012; 3: 9.